CIDRAP newsletters options
The P1 variant that caused a second wave of COVID-19 infections in Manaus, Brazil, is more transmissible and from 25% to 61% of previously infected people may be susceptible to reinfection, according to a preprint, non–peer-reviewed study from researchers at the University of Sao Paulo, Imperial College London, and the University of Oxford.
Also, the WHO details COVAX rollout and hot spot nations that contributed to a weekly rise in cases, the first in 6 weeks.
Two doses of the Pfizer vaccine were 85% to 90% effective against symptomatic illness in those 70 and older.
Low-resource nations have borne the brunt of shaky oxygen supply chains, even before COVID.
Also, some lawmakers ask officials to examine delaying 2nd vaccine doses.
Nearly three fourths of US women with an uncomplicated urinary tract infection get antibiotics longer than necessary.
After vaccination with an mRNA-based COVID-19 shot, antibody levels for immunoglobulin G (IgG) were higher in the short term in healthcare workers (HCWs) who had previous COVID-19 infections than those who had never had the disease, according to a research letter published yesterday in JAMA.
The Centers for Disease Control and Prevention (CDC) confirmed a new case of Listeria monocytogenes in an outbreak associated with queso fresco made by El Abuelito Cheese Inc, raising the total number of cases to 11.
After a 6-week decline, global COVID-19 cases are on the rise again, a worrisome development.
Instead of taking samples before and after travel, the researchers assessed daily samples.
The Guinea outbreak has reached 17 cases, and the CDC has issued public health and travel-related measures.
Availability of the J&J vaccine will be limited for weeks.
A review of 10 studies finds the therapy doesn't improve survival or clinical status or shorten hospital stays.
Israel's national COVID-19 vaccine rollout, which saw 84% of people 70 and older fully vaccinated by Feb 9 , was associated with less need for mechanical ventilation in the elderly. The finding could show that COVID-19 vaccine rollouts help prevent severe cases at the national level, according to a study in Morbidity and Mortality Weekly Report.
CARB-X announced today that it is awarding more than $10 million to GSK to develop vaccines to prevent serious infections caused by common bacterial pathogens that pose a significant health threat in the developing world.
Once the CDC gives the nod, distribution will start this week, with 2 million doses allocated to states.
The move gives the US a third vaccine to fight the pandemic—one that offers an easier, one-dose option that does not have to be frozen.
"We are left with evidence of benefit from interleukin-6 inhibitors, at least under some circumstances."
Now, it's up to FDA officials to make a final decision, which could come tomorrow.
Ten percent of cases are now caused by B117, up from 1% to 4% a few weeks ago.
